SRF analysts maintain their ‘sell’ rating on the stock after Chemours agreement

Brokerage firm UBS said that with ready fluoropolymers capacity, SRF is expected to see a major revenue uptick starting FY27E.

Leave a Reply

Your email address will not be published. Required fields are marked *